Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

Previous studies have suggested that many patients with myelodysplastic syndromes (MDS) have an incomplete understanding of their disease, which may influence adherence to prescribed regimens and outcomes.

[1]  David P Steensma,et al.  Myelodysplastic Syndromes: Diagnosis and Treatment. , 2015, Mayo Clinic proceedings.

[2]  H. Deeg,et al.  Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Voso,et al.  Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher‐risk myelodysplastic syndromes or chronic myelomonocytic leukemia , 2013, European journal of haematology.

[5]  M. Laouri,et al.  Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need , 2012, Transfusion.

[6]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[7]  B. Smith.  Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. , 2012, The American journal of medicine.

[8]  S. Kurtin,et al.  Patient and family resources for living with myelodysplastic syndromes. , 2012, Clinical journal of oncology nursing.

[9]  C. Cogle,et al.  Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. , 2011, Blood.

[10]  G. Mufti,et al.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.

[11]  J. Maciejewski,et al.  Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. , 2011, The oncologist.

[12]  H. Kantarjian,et al.  Cause of death in patients with lower‐risk myelodysplastic syndrome , 2010, Cancer.

[13]  D. Donley,et al.  A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS). , 2009 .

[14]  H. Kantarjian,et al.  Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. , 2008, Journal of the National Cancer Institute.

[15]  J. Sloan,et al.  Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. , 2008, Leukemia research.

[16]  H. Kantarjian,et al.  The incidence and impact of thrombocytopenia in myelodysplastic syndromes , 2007, Cancer.

[17]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[18]  David P Steensma,et al.  Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. , 2006, Leukemia research.

[19]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[20]  C. Bloomfield,et al.  Myelodysplastic syndromes clinical practice guidelines in oncology. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.